type-II collagen antibody (Abcam) and F4/80 (AbD Serotec) were used. Cell death inside articular cartilage was examined by TUNEL assay. Expression of catabolic, inflammatory, and anabolic factors such as MMP3, MMP13, cathepsin F, IL1b, IL6, type II collagen and type X collagen mRNA in cartilagious tissues of :7CKO and Cont mice was quantitated by Q-PCR. Results: In this study, we found that the absence of locally produced Bmp7 reduced proteoglycan contents in articular cartilage matrix in the adult mice (at 8 and 24 weeks of age). This may not be due to the defect in cartilage formation since there was no significant alteration in both articular structure and proteoglycan contents in the juvenile :7CKO mice (at 4 weeks of age). Structural analyses of articular cartilage indicated that cartilage thickness and chondrocyte density were not significantly altered between the genotypes at 8 and 24 weeks of age. TUNEL assay revealed that elimination of Bmp7 expression did not affect chondrocyte survival at 8 weeks of age. Histological evaluation revealed that extensive synovial hyperplasia was observed at 8 and 24 weeks of age in the absence of Bmp7. F4/80 staining revealed that extensive numbers of macrophages were infiltrated in the synovial tissues of :7CKO mice at these stages suggesting that severe synovitis occurred in the absence of Bmp7. In contrast, appearance of synovial membrane was quite similar between the genotypes at 4 weeks of age. Q-PCR analyses revealed that mRNA expression levels of all the genes examined (see above) in articular cartilage were not significantly altered between the genotypes at 24 weeks of age. Conclusions: Our data showed that the absence of endogenous Bmp7, although does not affect articular cartilage formation and survival of articular chondrocyte, but enhance articular cartilage degeneration and synovial inflammation in adult mice.
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EPIGENETIC MODIFYING COMPOUNDS ALTER ACTIVITY OF PRIMARY HUMAN ARTICULAR CHONDROCYTES AND MESENCHYMAL STEM CELLS UNDERGOING CHONDROGENESIS
S. Snelling, A. Kramm, C. Yapp, A. Carr, U. Oppermann. Univ. of Oxford, Oxford, United Kingdom Purpose: A major therapeutic challenge in osteoarthritis is to identify disease modifying therapeutics. No current therapies cause cessation or reversal of cartilage loss. Suitable therapeutics may target the chondrocytes or stem cells resident within the diseased cartilage or expanded in vitro prior to implantation. Epigenetic regulation of cell behavior is essential for both correct development and homeostasis of cartilage (1). This epigenetic control does not alter the DNA sequence and allows modifiable changes to gene expression that are heritable. Thus allowing a cell to respond to environmental and biological cues. Targeting the epigenetic modifying machinery can therefore provide important clues to the biology of chondrocyte differentiation and homeostasis and to potential targets for therapeutic intervention. Our library of epigenetic modifying compounds includes those targeting methyltrasnferases, histone deacetylases, histone protein kinases and bromodomains. In this preliminary work we have screened this library for impact on cell phenotype in chondrogenesis and in primary human articular chondrocytes (HAC) Methods: Primary human articular chondrocytes (HAC) and human mesencymal stem cells (MSCs) undergoing chondrogenesis were treated with epigenetic modifying compounds for 72 hours. Metabolic activity was assessed after 72h using Prestoblue before cells were fixed and assessed for cell number (DAPI count), ECM production (Alcian blue) and nodule formation (Nile Red). HAC were treated with GSK-J4 and GSK-J5 for 6h and TIMP3 and COL2A1 expression assessed by qPCR. HAC were treated with GSK-J4 and GSK-J5 for 3h in the presence and absence of 2ng/ml TGFb and expression JMJD3 and the TGFb target gene TIMP3 was assssed by qPCR. Results: Compounds including Methylstat, an inhibitor of the Jumonji C domain-containing histone trimethyl demethylases caused an increase in the metabolic activity and cell number of MSCs and HAC, whilst 5-iodotubercidin increased metabolic activity in MSCs only. GSK-J4, which blocks H3K27 demethylation decreased metabolic activity and cell number in MSCs and HAC. ECM accumulation in chondrogenesis were reduced by compounds including GSK-J4 whilst ECM accumulation was increased by the PARP inhibitor Rucaparib. COL2A1 and TIMP3 expression was reduced in HAC treated with GSK-J4, but not HAC treated with the inactive isomer GSK-J5. Treatment of HAC with TGFb increased the expression of the H3K27 demethylase JMJD3 and the TGF-responsive gene TIMP3. In the presence of GSK-J4 the TGFinduced JMJD3 and TIMP3 expression was inhibited.
Conclusions: This preliminary screen demonstrates the utility of epigenetic modifying compounds in the regulation of chondrogenesis and HAC behavior. We have shown that epigenetic regulation can both enhance and inhibit chondrogenesis and can also alter the phenotype of HAC. The differential effects of compounds in HAC and MSC indicates the importance of fine and temporally correct regulation of epigenetic activities during chondrocyte differentiation and homeostasis. Early investigations on the role of GSK-J4, which inhibits the histone demethylase JMJD3, in HAC suggest JMJD3 as an important epigenetic target through its ability to regulate TGFb signaling. Purpose: The TGFb signalling pathway has been shown to play a major role in joint homeostasis and in osteoarthritis development. Fibrillin-1 is an extracellular matrix protein that may play a structural role in the matrix of articular cartilage. Fibrillin rich microfibrils (especially fibrillin-1) help in the regulation of TGFb activity by controlling its bioavailability to the cell. Thus Fibrillin-1 mutations, such as those seen in the Tight Skin mouse (or TSK), have been shown to increase TGFb signalling. The TSK mouse displays tight skin, myocardial hypertrophy, marfan-like skeletal phenotype and lung emphysema, but no studies have yet investigated the effect of Fibrillin-1 mutation on joint health. The aim of this study is therefore to determine changes in fibrillin-1 expression during osteoarthritis in mice and to characterise the effect of Fibrillin-1 mutations in ageing-induced OA development in TSK mice. Methods: Immunohistochemistry for Fibrillin-1 expression was performed in Str/ort mice, a known model of spontaneous OA, and in control aged-matched non-OA CBA mice, in knee joints with different degrees of OA severity. The knees of TSK and littermate control male mice of 60-80wks of age were fixed and microCT scanned. Abnormal ectopic calcified regions were analysed. After scanning, joints were decalcified and processed for paraffin embedding; serial coronal sections were cut at 6um and sections at regular intervals stained with Toluidine Blue. Results: Fibrillin-1 was localised in the pericellular matrix of articular chondrocytes in normal joints. During the development of OA in Str/ort mice, however, Fibrillin-1 immunolabelling was decreased, in particular around articular cartilage lesions. TSK mice microCT images showed important ectopic calcification and ossification in various ligaments, including patella and collateral ligaments, as well as osteophyte formation on the margins of the joints. Preliminary data suggest that articulate cartilage degradation was increased in TSK mice compared to aged-matched control mice suggesting a role of Fibrillin-1 in joint health and osteoarthritis development. Conclusion: Our preliminary study shows that Fibrillin-1 protein expression is decreased during OA development in a well known model of spontaneous OA, suggesting TGFb bioavailability may be modified during this period. In addition, mutations in Fibrillin-1 in the TSK mouse lead to abnormal ossification in the knee joint as well as severe OA development. These data suggest that Fibrillin-1 plays an important role in joint homeostasis and that abnormal expression or mutations in its gene can lead to OA development.
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